Sign In
Buy JAZZ
$230.93
+4.81 (+2.13%)
At Close: Jun 03, 2026
Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q1 2021 Results - Earnings Call Transcript
10:48pm, Tuesday, 04'th May 2021
Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q1 2021 Results - Earnings Call Transcript
Jazz Pharmaceuticals (JAZZ) Beats Q1 Earnings and Revenue Estimates
08:17pm, Tuesday, 04'th May 2021
Jazz (JAZZ) delivered earnings and revenue surprises of 6.23% and 0.16%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
GW Pharmaceuticals Stockholders Approve Acquisition by Jazz Pharmaceuticals
07:20pm, Friday, 23'rd Apr 2021
Jazz is about to get the top cannabis-derived drug on the market, in addition to a robust pipeline.
4/20 Holiday Week Had These Cannabis Stocks Fired Up
01:05pm, Friday, 23'rd Apr 2021
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week, and look ahead to how the cannabis industry will co
Jazz Pharmaceuticals Prices $1.5 Billion Senior Secured Notes Offering
05:01pm, Thursday, 22'nd Apr 2021
DUBLIN, April 22, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the "Company" or "Jazz") today announced the pricing of the previously announced offering (the "Offering") of $1.5 bill
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
12:46pm, Thursday, 22'nd Apr 2021
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Enhance Your Portfolio With These 6 Low Price-to-Book Stocks
07:31am, Thursday, 22'nd Apr 2021
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects
Jazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured Notes
08:45am, Tuesday, 20'th Apr 2021
DUBLIN, April 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the "Company") announced today that its wholly owned subsidiary, Jazz Securities Designated Activity Company (the "Issu
DUBLIN, April 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from the Phase 3 study of XywavTM (calcium, magnesium, potassium, and sodium oxybates)
Jazz Pharmaceuticals to Report 2021 First Quarter Financial Results on May 4, 2021
04:05pm, Monday, 19'th Apr 2021
DUBLIN, April 19, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 first quarter financial results on Tuesday, May 4, 2021 after the close of
JAZZ's Xywav sNDA for Hypersomnia Gets FDA Priority Review
10:37am, Tuesday, 13'th Apr 2021
JAZZ focuses on expanding label of its recently approved sleep drug, Xywav - a low sodium-formulation of Xyrem.
DUBLIN, April 12, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation and confirmed th
A Cannabis Pro Tells Us Her Hopes for the Medical Marijuana Industry
06:00am, Monday, 12'th Apr 2021
2020 was a big year for the cannabis industry, but 2021 is shaping up to be even bigger.
Healthcare Investors: Here's What You Need to Know About Medical Marijuana
06:15am, Sunday, 11'th Apr 2021
Although research on the medical benefits of the drug is limited in the U.S., we have some ideas about marijuana's ability to disrupt the healthcare industry.
These 2 Stock Market Plays Are Moving Up the Charts in 2021
05:02pm, Wednesday, 07'th Apr 2021
Could these areas see more gains ahead?
